Ceritinib

Systematic (IUPAC) name
5-Chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine
Clinical data
Trade names	Zykadia
AHFS/Drugs.com	Multum Consumer Information
Pregnancy category	US: D (Evidence of risk)
Legal status	US: ℞-only
Routes of administration	Oral
Identifiers
CAS Number	1032900-25-6
ATC code	L01XE28 (WHO)
PubChem	CID: 57379345
DrugBank	DB09063
ChemSpider	29315053
KEGG	D10551
ChEBI	CHEBI:78432
ChEMBL	CHEMBL2403108
Synonyms	LDK378
Chemical data
Formula	C28H36ClN5O3S
Molecular mass	558.14 g/mol
SMILES CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
InChI InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) Key:VERWOWGGCGHDQE-UHFFFAOYSA-N

Ceritinib (trade name Zykadia) is a drug for the treatment of a specific type of lung cancer. It is an anaplastic lymphoma kinase (ALK) inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.